155 related articles for article (PubMed ID: 34674665)
1. Real-life isoniazid and rifampicin plasma concentrations in children: a tool for therapeutic drug monitoring of tuberculosis.
Tersigni C; Boiardi G; Tofani L; Venturini E; Montagnani C; Bortone B; Bianchi L; Chiappini E; Cassetta MI; Fallani S; Novelli A; Galli L
BMC Infect Dis; 2021 Oct; 21(1):1087. PubMed ID: 34674665
[TBL] [Abstract][Full Text] [Related]
2. Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India.
Ranjalkar J; Mathew SK; Verghese VP; Bose A; Rose W; Gupta D; Fleming DH; Mathew BS
Int J Antimicrob Agents; 2018 May; 51(5):663-669. PubMed ID: 29241821
[TBL] [Abstract][Full Text] [Related]
3. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
Justine M; Yeconia A; Nicodemu I; Augustino D; Gratz J; Mduma E; Heysell SK; Kivuyo S; Mfinanga S; Peloquin CA; Zagurski T; Kibiki GS; Mmbaga B; Houpt ER; Thomas TA
J Pediatric Infect Dis Soc; 2020 Feb; 9(1):14-20. PubMed ID: 30395239
[TBL] [Abstract][Full Text] [Related]
5. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
Thee S; Seddon JA; Donald PR; Seifart HI; Werely CJ; Hesseling AC; Rosenkranz B; Roll S; Magdorf K; Schaaf HS
Antimicrob Agents Chemother; 2011 Dec; 55(12):5560-7. PubMed ID: 21968358
[TBL] [Abstract][Full Text] [Related]
8. Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients.
Kumar AKH; Chandrasekaran V; Kannan T; Lavanya J; Swaminathan S; Ramachandran G
Indian J Med Res; 2018 Mar; 147(3):287-292. PubMed ID: 29923518
[TBL] [Abstract][Full Text] [Related]
9. Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid.
Ray J; Gardiner I; Marriott D
Intern Med J; 2003; 33(5-6):229-34. PubMed ID: 12752892
[TBL] [Abstract][Full Text] [Related]
10. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status.
Dayal R; Singh Y; Agarwal D; Kumar M; Swaminathan S; Ramachandran G; Kumar S; Narayan S; Goyal A; Kumar AKH
Arch Dis Child; 2018 Dec; 103(12):1150-1154. PubMed ID: 29514812
[TBL] [Abstract][Full Text] [Related]
12. Isoniazid hair concentrations in children with tuberculosis: a proof of concept study.
Mave V; Chandanwale A; Kinikar A; Khadse S; Kagal A; Gupte N; Suryavanshi N; Nimkar S; Koli H; Khwaja S; Bharadwaj R; Joshi S; Horng H; Benet LZ; Ramachandran G; Dooley KE; Gupta A; Gandhi M
Int J Tuberc Lung Dis; 2016 Jun; 20(6):844-7. PubMed ID: 27155191
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
[TBL] [Abstract][Full Text] [Related]
14. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?
Trentalange A; Borgogno E; Motta I; Antonucci M; Pirriatore V; Costa C; Rossi G; Barco A; De Nicolò A; Piccioni P; D'Avolio A; Bonora S; Di Perri G; Calcagno A
Int J Antimicrob Agents; 2021 Mar; 57(3):106297. PubMed ID: 33539932
[TBL] [Abstract][Full Text] [Related]
15. Serum concentrations of rifampicin and isoniazid in tuberculosis.
Seth V; Beotra A; Seth SD; Semwal OP; Kabra S; Jain Y; Mukhopadhya S
Indian Pediatr; 1993 Sep; 30(9):1091-8. PubMed ID: 8125594
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
Martial LC; Kerkhoff J; Martinez N; Rodríguez M; Coronel R; Molinas G; Roman M; Gomez R; Aguirre S; Jongedijk E; Huisman J; Touw DJ; Pérez D; Chaparro G; Gonzalez F; Aarnoutse RE; Alffenaar JW; Magis-Escurra C
Int J Antimicrob Agents; 2018 Jul; 52(1):109-113. PubMed ID: 29751121
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
[TBL] [Abstract][Full Text] [Related]
18. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels.
Um SW; Lee SW; Kwon SY; Yoon HI; Park KU; Song J; Lee CT; Lee JH
Int J Tuberc Lung Dis; 2007 Sep; 11(9):972-8. PubMed ID: 17705974
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes.
Labana S; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2002 Oct; 20(4):301-4. PubMed ID: 12385689
[TBL] [Abstract][Full Text] [Related]
20. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
